Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

Revenue projections:

Revenue projections for CAPLIPOINT
Revenue projections for CAPLIPOINT

CAPLIPOINT's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 18.613537
debtToEquity 0.166000
earningsGrowth 0.183000
revenueGrowth 0.101000
grossMargins 0.592320
operatingMargins 0.313960
trailingEps 80.490000
forwardEps 91.600000

CAPLIPOINT's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
CAPLIPOINT's positive earnings and revenue growth reflect a strong outlook for the company's business expansion. The company is expected to continue growing, with increasing profitability and sales driving further growth in the near future.
CAPLIPOINT's positive gross and operating margins indicate a profitable and efficient business model. These metrics highlight the company's ability to generate income while controlling operational costs, reflecting strong financial performance.
CAPLIPOINT's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for CAPLIPOINT
Price projections for CAPLIPOINT

Caplin Point Laboratories Limited's current price shows alignment with projections, offering no clear risks or opportunities. This neutral stance indicates a stable market environment, where investors may prefer to maintain their positions until more compelling information surfaces.

Recommendation changes over time:

Recommendations trend for CAPLIPOINT
Recommendations trend for CAPLIPOINT


With analysts showing a buy bias for CAPLIPOINT, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning CAPLIPOINT as a safe and profitable place for investors to allocate their funds and seek growth.